Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison

•Herein, we investigated the real-world efficacy of nivolumab and cabozantinib as second-line therapy in a cohort of 343 patients in a real-world setting.•We observed an advantage for nivolumab in terms of overall survival (OS) in almost all the subgroups analyzed, without reporting a statistically...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical genitourinary cancer 2022-06, Vol.20 (3), p.285-295
Hauptverfasser:	Santoni, Matteo, Aurilio, Gaetano, Massari, Francesco, Grande, Enrique, Matrana, Marc R, Rizzo, Mimma, De Giorgi, Ugo, Incorvaia, Lorena, Martignetti, Angelo, Molina-Cerrillo, Javier, Zabalza, Ignacio Ortego, Mollica, Veronica, Rizzo, Alessandro, Battelli, Nicola, Porta, Camillo
Format:	Artikel
Sprache:	eng
Schlagworte:	Anilides - therapeutic use Cabozantinib Carcinoma, Renal Cell - drug therapy Humans Immunotherapy Kidney Neoplasms - drug therapy Nivolumab Nivolumab - therapeutic use Prognostic Factors Pyridines Renal Cell Carcinoma Retrospective Studies Survival
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!